Published • loading... • Updated
Antengene Presents Key R&D Highlights at the Evercore 2nd China Biotech Summit
- Antengene Corporation Limited presented key R&D highlights at the Evercore 2nd China Biotech Summit during a fireside chat.
- The company shared updated clinical data for ATG-022, a CLDN18.2 antibody-drug conjugate .
- Antengene showcased its proprietary T-cell engager platforms AnTenGager® and TriGager™, introducing multiple new functional modules.
- The company detailed clinical development plans for ATG-022 in various gastric cancer treatment lines, including combinations with anti-PD-1 antibodies and chemotherapy.
Insights by Ground AI
29 Articles
29 Articles
The Herald-Dispatch+28 Reposted by 28 other sources
Antengene Presents Key R&D Highlights at the Evercore 2nd China Biotech Summit
SHANGHAI and HONG KONG, Aug. 18, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies,…
Coverage Details
Total News Sources29
Leaning Left3Leaning Right4Center19Last UpdatedBias Distribution73% Center
Bias Distribution
- 73% of the sources are Center
73% Center
12%
C 73%
15%
Factuality
To view factuality data please Upgrade to Premium
